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“Science, my lad, is made up of mistakes, but they are mistakes which it is useful to make, 
because they lead little by little to the truth.” 







Cardiovascular diseases (CVDs) are a prominent health problem, being the leading cause of 
death worldwide. Numerous studies have been focus on the beneficial effects of dietary (poly)phenols, 
as a way to prevent the onset of CVDs. 
 Recently, a link between CVDs, metabolism, mitochondria and diet has been evidenced. This 
link might involve a crosstalk between mitochondria functions, autophagy and cell death and would 
be regulated at the cellular level by various classes of sensors such as proteins as well as second 
messengers. 
 The purpose of this study is to evaluate the potential of novel berries driven (poly)phenols 
(BDP) metabolites in cardioprotection and unravel the BDP-targeted cytoprotective mechanisms 
namely in mitochondrial functionality. Therefore studies were conducted using H9c2 cells and 
neonatal rat cardiomyocytes treated with tert-butyl hydroperoxide or isoproterenol to promote cell 
death, modeling chronical cardiac diseases.  
Analysis of mitochondrial population, in neonatal rat cardiomyocytes and H9c2 cells 
respectively, showed that BDP metabolites induce an increase of mitochondrial population. Moreover 
BDP metabolites appear to not protect against cell death induced by isoproterenol activated pathway. 
An important finding in this work was that BDP metabolites are capable of improving cardiac 
contractile functions, without decreasing isoproterenol induced cell death. 
 Although not completely conclusive, the obtained results support a need for future research, 
as these compounds can be promising therapeutic agents in CVDs prevention fostering an active and 
healthy ageing. Given the growing number of cardiovascular incidents, being able to possibly develop 
a prophylactic drug against CVDs, would be a great achievement. Creating a prophylactic drug from 
BDP metabolites, would help people with a propensity to CVDs keeping a higher quality of life and 




















As doenças cardiovasculares são consideradas um dos mais importantes problemas de saúde, 
sendo apontadas como a principal causa de morte no mundo. Inúmeros estudos têm vindo a ser 
desenvolvidos no âmbito da prevenção deste tipo de doenças tendo como base os efeitos benéficos 
dos polifenóis provenientes da dieta. 
Trabalhos recentes propõe que a ligação existente entre as doenças cardiovasculares e a dieta 
deve-se maioritariamente à regulação da autofagia e metabolismo celular realizado pelas 
mitocôndrias.   
Este trabalho tem como finalidade avaliar o potencial cardioprotetor dos metabolitos de 
polifenóis de pequenos frutos, focando-se no estudo dos mecanismos citoprotetores e interação com 
a mitocôndria. Por forma a realizar estes estudos recorreu-se à linha celular H9c2 e cardiomiócitos de 
rato neonatal tratados com terc-butil-hidroperóxido ou isoproterenol de forma a mimetizar doenças 
cardiovasculares crónicas. 
Resultados obtidos da análise à população mitocondrial e ao metabolismo celular 
evidenciaram alterações associadas ao pré-tratamento com os metabolitos de polifenóis de pequenos 
frutos. Contudo, resultados obtidos com isoproterenol apontam para uma ausência de interação entre 
os metabolitos de polifenóis de pequenos frutos e a morte celular induzida pelo isoproterenol. A 
descoberta mais importante deste trabalho, deve-se no entanto à capacidade dos metabolitos de 
polifenóis de pequenos frutos conseguirem melhorar a capacidade contrátil das células, quando estas 
estão expostas a stresse. 
Este trabalho apresenta resultados que demonstram uma necessidade em continuar a explorar 
os metabolitos testados. Devido ao crescente número de incidentes cardiovasculares, o 
desenvolvimento de novos agentes terapêuticos capazes de prevenir o aparecimento de doenças 
cardiovasculares torna-se uma prioridade. A utilização de metabolitos de polifenóis de pequenos 
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1.1. Cardiovascular diseases 
 
Cardiovascular diseases (CVDs) are defined as a group of disorders that affect heart, blood 
vessels or both and encompass all of coronary artery disease, hypertension, congestive heart failure 
and stroke. CVDs have been seen as a prominent health problem as the main cause of death in 
developed countries, and account for 30% of the deaths worldwide according to World Health 
Organization (WHO) 1,2. Firstly, CVDs were characterized as diseases of middle age adults, mainly men. 
Nevertheless, recent studies have proven that vascular injuries can accumulate throughout life making 
prevention necessary since childhood. Furthermore, there is an important relation between 
cardiovascular risk factors (smoking, arterial hypertension, hypercholesterolemia, 
hypertriglyceridemia, diabetes and obesity) and cardiovascular mortality, as the existence of 
cardiovascular risk factors are correlated with an increase in the possibility of CVDs and a greater 
probability of mortality after a cardiovascular event 1. 
Heart is composed of multiple cell types such as cardiomyocytes (which constitute 30% of the 
total cell number but account for 70-80% of the hearts weight), fibroblasts, vascular smooth cells, 
endothelial cells and immune cells 3. 
The ability to supply oxygenated blood to the body can be lost due to exposure to pressure or 
volume overload (e.g., hypertension, valvular heart disease), myocardial infarction (MI) or ischemia. 
Cardiac hypertrophy is the compensatory response to the diminished capability of the heart to supply 
oxygenated blood and consists in the increase in size and mass of the heart in order to normalize wall 
stress and allow normal cardiovascular function. Cardiomyocytes do not possess the ability to divide, 
thus compensatory response to cardiac hypertrophy is associated with cardiomyocyte enlargement. 
Cardiac hypertrophy compensatory response is also followed by alterations in calcium handling, 
metabolism, gene expression, cell death (e.g., apoptosis and autophagy), changes in extracellular 
matrix (ECM), development of fibrosis, and angiogenesis 3. Although cardiac hypertrophy occurs in 
order to maintain cardiac function, continued stress will lead to ventricular dilatation and diminished 
contractile capability eventually progressing to heart failure 3,4. 
 
1.2. Oxidative stress in cardiovascular health 
 
Elevated levels of reactive oxygen species (ROS) or reactive nitrogen species (RNS) or both 
within the cells, leads to oxidative stress that has been implicated in heart failure, atherosclerosis and 
hypertension. Oxidative stress can be define as an imbalance between the production of reactive 
species and antioxidants defenses, which can result from the accumulation of highly reactive free 
radicals species or the decrease in the defense mechanisms capable of eliminating the free radicals 5, 
6. In a state of oxidative stress there is a change in the cell redox state that interferes with important 
physiological processes, which may cause mitochondrial dysfunction, DNA damage and apoptosis, 
triggering the initiation of several diseases 7,8. 
ROS and RNS that are biologically produced from metabolic reactions and these processes can 
have or not enzymatic origin 5. Some ROS are radical species, such as superoxide anion (O2-·), hydroxyl 
radical (OH·), peroxyl radical (ROO·), and hydroperoxyl radical (HOO·). Hydrogen peroxide (H2O2) and 
hypochlorous acid (HOCl) are also part of the ROS family; although they are not free radicals. The RNS 
include free radicals such as nitric oxide (NO·) and nitrogen dioxide (NO2·). Peroxynitrite (ONOO-) is the 
non-free radical RNS 5. 
As stated before, oxidative stress is tightly implicated with CVDs, as the major mechanism of 
endothelial dysfunction observed in CVDs comes from the reaction of O2-· with NO· resulting in ONOO- 
.This potent oxidant is capable of lipid peroxidation, activation of stress signaling and matrix 
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metalloproteinases, inactivation of enzymes and other proteins by oxidation and nitration such as α-
actinin, myofibrillar creatine kinases and prostacyclin synthase damaging the contractile function of 
myofilaments 9. The decomposition of ONOO- results in toxic products such as the highly reactive OH· 
and NO2· 14,15,16. Furthermore a continued production of ONOO- can trigger mitochondrial membrane 
permeabilization and release of proapoptotic factors such as cytochrome c (Cyt c) and apoptosis-
inducing factor (AIF) from the mitochondria. These factors, mediate caspase-dependent and 
independent apoptotic death pathways. In addition to these reactions, ONOO- in association with other 
oxidants causes strand breaks in DNA which leads to the activation of the nuclear enzyme poly(ADP-
ribose) polymerase-1 (PARP-1) 10. 
During a cardiovascular pathology, once there is extensive oxidative damage to the DNA, PARP-
1 is overactivated resulting in a rapid depletion of cellular ATP and NAD+, slowing the rate of glycolysis 
and mitochondrial respiration. Overactivation of PARP-1 can also result in an increased expression of 
a variety of inflammatory genes leading to increased inflammation and associated oxidative stress, 
therefore facilitating the progression of cardiovascular dysfunction and heart failure (Fig. 1-1) 10. 
Although ONOO- is a very harmful RNS its precursor NO· is essential for a normal cardiovascular 
physiology. Nitric oxide is important in different cardiac functions such modulation of cardiac 
contractile function, inhibition of cardiac oxygen consumption and activation of the soluble guanylate 
cyclase cyclic guanosine monophosphate ((sGC)-cGMP). Moreover the sGC-cGMP signal pathway 
mediates vasodilation, inhibition of platelet aggregation and neutrophil adhesion and activation, anti-
inflammatory, antiremodelling and antiapoptotic effects 10. 
 
 




1.3. Mitochondrial oxidative stress  
 
Mitochondrial respiration is the major source of ROS in mammals under physiological 
conditions, being the mitochondrial electron transport chain (mtETC) responsible for it. The mtETC is 
a sequence of the Complexes I-IV located in the mitochondria inner membrane and arrayed in a 
supramolecular organization with the purpose of producing ATP through a process of oxidative 
phosphorylation. Unpaired electrons are a natural consequence of mitochondrial respiration as 
electrons leak from several mtETC sites. As such, during mitochondrial respiration, closely to 1 % – 3 % 
of electrons leak, as a result there is formation of O2-· 7. 
Complex I and III are the main sources of O2-· generation within all mtETC 6,11,12. Complex I 
production of O2-· occurs in vivo when NADH levels are high, there is damage to the respiratory chain, 
slow respiration or ischemia. The production of O2-· in Complex I may possibly be from the iron sulfur 
center 2 or the mitochondrial NO synthase. Whereas   Complex III-derived O2-· derives from an electron 
leak to oxygen at the ubiquinone site interface between Complexes II and III 11,12. 
 While the radical O2-· generated from Complex I is released into the mitochondrial matrix the 
Complex III-derived O2-· is released into both the mitochondrial matrix and the intermembrane space. 
Mitochondria possesses superoxide dismutase (SOD) enzymes in the mitochondrial matrix and in the 
intermembrane space, SOD2 and SOD1 respectively, with the purpose of dismutate O2-· in to H2O2 
preventing therefore the formation of ONOO- 6. Although the generation of unpaired electrons is a 
natural by-product of mitochondrial respiration ROS production can be regulate through the 
mitochondrial membrane potential.  
Recent studies have suggested that at extremes of overall mitochondrial membrane potential 
would lead to an increase in pathophysiological ROS levels. This fact can be observed during hypoxia 
when mitochondrial membrane potential is significantly reduced or during  an heart failure when an 
intensification in workload significantly increases mitochondrial membrane potential and there is also 
an increase in ROS production 11,12.  
Even though ROS and RNS can produce extensive oxidative damage within the cell, this only 
happens in face of an endogenous antioxidant system dysfunction, otherwise cells during their 
physiological processes of energy generation produce a significant amount of ROS/RNS which is mainly 
storage within intact mitochondria. Furthermore the fact that ROS/RNS might possess a physiological 
role as been increasingly accepted. Namely in a functional system the production of ROS/RNS is in fact 
beneficial for the cell as it is involved as mediators of signal transduction, activation of proteins, 
expression of genes associated with the immune and inflammatory response, defense against 
infections agents, regulation of the G1 phase an also in the differentiation of embryonic cell lines into 
cardiomyocytes 7.  
  
1.4. Mitochondrial dysfunction in CVDs 
 
 As aforementioned mitochondria are a very important organelles in cardiac physiology as they 
are the principal ATP generator and can influence cardiac development and remodeling into adult cells. 
Thus when mitochondria dysregulation happens, it influences the pathophysiological processes of 
CVDs 13.   
Under a pathophysiological state where an increase in contractile functions is demanded, the 
best way to enhance energy production is to stimulate new mitochondrial production, termed 
mitochondrial biogenesis 14. Nevertheless during a state of continued oxidative stress, cardiomyocyte 
mitochondria becomes dysfunctional presenting a reduced ATP synthesis, abnormal accumulation of 
metabolic intermediates, calcium dysregulation and increased ROS production 15.  
Mitochondria are very dynamic organelles and can even within a single cell possess different 
sizes, morphology, and copy numbers of mitochondrial DNA (mtDNA). These differences exists as 
result of an important form of mitochondria quality control that occurs in a constant flux. This process 
of quality control mainly consists in mitochondria going through a perpetual fusing with each other 
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and dividing. Mitochondria dynamic system of continuous fission and fusion events, enables the 
control of their morphology, integrity and function 16. Fission events are required for normal 
mitochondrial functions while fusion events allow the mixing of mitochondrial genomes as a way of 
diminishing the quantity of damaged DNA 15, 14.  
Although quality control is important to keep a high percentage of functional mitochondria, 
when facing an increasing cardiac workload it is necessary to enhance mitochondrial biogenesis, as 
aforementioned. Mitochondrial biogenesis is mainly associated to an increase in activity from the 
nuclear encoded protein, peroxisome proliferator-activated receptor gamma coactivator alpha (PGC-
1α) 14,17. Through transgenic mouse models the role of PGC-1α in the heart have been extensively study 
17. However the role of PGC-1α during CVDs and heart failure in humans remains controversial as 
contradictory results have been reported 14,18. On the other hand it has been demonstrated that 
estrogen-related receptor alpha, an orphan nuclear receptor required for PGC-1α dependent 
mitochondrial biogenesis, is downregulated during heart failure contributing  to the decrease in 
transcription of some nuclear encoded mitochondrial proteins 18,19. 
During CVDs, prolonged exposure of mitochondria to oxidative stress lead to the impairing of 
mitochondrial biogenesis through disruption of mitochondrial renewing mechanisms and induction of 
DNA damage 15. Mitochondrial DNA is considerably more susceptible to oxidative stress compared to 
nuclear DNA, having a mutational rate 10-fold higher 13. This high mutational rate is observed mainly 
due to the proximity of mtDNA with the mtETC , the lack of protective histones and chromatin and the 
dependence in a basic DNA repair process such as base excision repair 15.  
 
1.5. Diet contribution to CVDs 
 
Although CVDs are a global problem their incidence varies from country to country in part due 
to different nutritional habits as it has been observed from epidemiologic studies. The “Seven 
Countries Study” observed a lower incidence of CVDs in countries with a Mediterranean diet (MD), 
being this diet characterized by a high intake of olive oil, fruits, vegetables, cereals (mainly whole grain 
cereals), nuts, and seeds; a moderate consumption of fish, seafood, poultry, and eggs; and a low 
consumption of dairies, red meat, processed meat, and sweets 1,20. Another study that showed the 
impact of the MD was the PREDIMED trial which included 7,447 high-risk participants initially free of 
CVDs that for 5 years followed one of three dietary interventions being one the control (advised in on 
a low-fat diet) and the others MD supplemented with extra virgin olive oil or nuts (walnuts, almonds, 
and hazelnuts) 21. The diets supplemented with virgin oil or nuts brought in a reduction of 30 % of 
major cardiovascular events in comparison to the control diet 20,21.   
 A great number of studies aiming to prevent the appearance or to improve the outcome of 
CVDs have showed that the consumption of fruits and vegetables helps preventing the appearance of 
CVDs 22. The preventive effect of fruits and vegetables has been linked to the presence of phenolic 
compounds 2,23. These phenolic compounds have been designated as (poly)phenols and are 
characterized structurally by possessing one or more phenolic hydroxyl groups 24. (Poly)phenols can be 
divided into two groups, flavonoids and non-flavonoids (Fig. 1-2). Flavonoids are characterized by a 
structural backbone of C6-C3-C6 and are sub divided according to their side chain into flavones, 
isoflavones, flavanones, flavonols, flavanols and anthocyanins. Non-flavonoids include molecules such 










1.6. (Poly)phenols in cardioprotection  
 
Recently (poly)phenols from dietary sources have started to take a central role in the search 
for bioactive compounds against CVDs and other diseases. There has been an increasing number of 
experimental studies using dietary (poly)phenols. However, almost all of them consists of in vitro 
studies with the direct application of purified (poly)phenols to the target cell culture. There was no 
regard for the reduced bioavailability of (poly)phenols reaching the target tissues in vivo 7. Moreover, 
it must also be taken into account the molecular changes occurring after ingestion, such as changed 
bioactive properties 7. Bioavailability is considered to be the fraction of a compound that reaches the 
systemic circulation and the specific sites of action and can exert its biological role. In the absorption 
of dietary (poly)phenols there are factors that can be a critical determinant for it, namely: the 
interaction of (poly)phenols with the gut microbiota, differential expression of efflux pump genes,  and  
liver metabolism. Furthermore, some (poly)phenols can be reduced to metabolites with a different 
biological activity or with an increased rate of clearance 7,26.  
Most dietary (poly)phenols exist within food as polymers or in a glycosylated form and cannot 
be directly absorbed. In order for (poly)phenols glycosides to be absorbed, they must be first 
hydrolyzed by the intestinal enzymes or by the colonic microflora 27,28,29. After absorption, 
(poly)phenols undergo further metabolization within the liver through the conjugation process 
common to xenobiotics. This conjugation process consists in the phase II metabolism with methylation, 
sulfation and glucuronidation, but the type of conjugation change depending on the substrate 29,28. As 
a consequence of these processes, generally there are not many parent compounds circulating in 
plasma. However, it is possible to identify several different molecules as metabolites with possibly 
distinct biological activity from their predecessor 28. 
 (Poly)phenols are well known for their  antioxidant capacity in vitro, mainly due  their aromatic 
structure with a highly conjugated system of pi electrons configuration and some hydroxylation 
patterns, that enables them to capture an electron thus neutralizing free radicals 27. Although their 
antioxidant capacity derives from their structure, as previously mention the same is not fully conserved 
after digestion 29. Furthermore, the concentration of (poly)phenols reaching tissues is much lower than 
the used ones for characterization as antioxidant molecules 30.  
Thus far a numerous of studies have revealed a clear interaction between different types of 
dietary (poly)phenols and activation of the protein kinase B (Akt) signaling pathway that is responsible 
for inducing mitochondrial biogenesis, muscle hypertrophy, cardiac growth, survival metabolism, and 
contractility 31–35. It has been also reported that metabolized (poly)phenols can inhibit some enzymes 
such as angiotensin-converting enzyme and xanthine oxidase or induce the expression of endothelium 
nitric oxide synthase (eNOS) and SOD enzymes, which are all linked to cellular regulation of oxidative 
stress 2,25.  
Even though, the direct antioxidant capacity of (poly)phenols is not completely conserved after 
digestion, their metabolized intermediates can target a wide-ranging of different proteins, which in 
























































































1.7. Berries Driven (Poly)phenols 
 
 Most recent works that take into account dietary (poly)phenols metabolization are important 
to highlight 36,37, as little attention has been given to the actual (poly)phenols metabolites circulating 
and their physiologic concentration. As mentioned before, numerous epidemiologic and experimental 
studies suggest a vast number of health benefits from (poly)phenol ingestion, without taking into 
account which metabolites are truly active and if they are even able to reach the target tissue 28.   
 With the propose of  shedding light into what can truly be found circulating within the human 
body, intervention studies have come to great lengths in helping the scientific community 
understanding the metabolic fate and bioavailability of ingested compounds 28,38.  Intervention studies 
are commonly used in order to evaluate the efficiency of a therapeutic or preventive measure, as 
followed subjects are compared to a control group. In epidemiologic studies, interventions studies are 
considered to be the ones that provide the most reliable evidence 39. 
 It has long been known that berries possess a high content of (poly)phenols,40 and an elevated 
contribution to the overall ingestion of (poly)phenols in comparison to other food sources41. 
Notwithstanding all the existing studies with berries driven (poly)phenols there is still a gap needed to 
be filled, as little is known about which metabolites and conjugates produced after consumption are 
actually active. A recent intervention study performed in Dr Cláudia Santos laboratory using a berries 
mixture (blueberries, raspberries, blackberries, Portuguese crowberry, and strawberry tree fruits) as 
the only (poly)phenol source in the volunteers diet, identified, plasma levels and the excretion rate of 
(poly)phenols metabolites 36,37.  
1.8. Mitochondria as a therapeutic target against CVDs 
 
Playing mitochondria dysfunction an important role in CVDs, new therapeutic strategies based 
on mitochondria as target have been studied to prevent or to improve CVDs outcomes 14,42.  
 In search for novel cardioprotective therapies through mitochondrial regulation, (poly)phenols 
from dietary sources have acquired an important role, mainly due to all the extensive research done 
showing the cardioprotective effect of the different groups of (poly)phenols 42. Majority of the 
beneficial effects showed by (poly)phenols may rest in their ability to interact with  mitochondrial 
biogenesis and  regulation of apoptotic pathways. For instance some (poly)phenols can upregulate 
PGC-1α, while others like flavanols can inhibit apoptotic signaling pathways. Anthocyanins another 
class of (poly)phenols can affect mitochondria from apoptosis modulation to the regulation of 
mitochondrial membrane  potential, respiratory chain and mitochondrial permeability 42–47.  
 Although there is a vast amount of promising results, the pathways of these active compounds 
are still not completely known, thus a numerous of different aspects are yet to be study before there 












































Cardiovascular diseases constitute a prominent health problem, as it is account for 30% of the 
deaths worldwide. It has been evidenced a link between CVDs progression, mitochondria, and diet. 
The knowledge of these interactions opens many possibilities for development of new therapeutic 
agents in CVDs prevention.  
In order to gain insight of the novel berries driven (poly)phenols (BDP) protective potential 
against CVDs, a set of specific aims were establish: (i) evaluation of BDP on cell death modulation;  (ii) 
BDP role on mitochondrial biogenesis by assessment of mitochondrial population; and (iii) evaluation 
of BDP on cardiomyocyte beating activity. 
To achieve these aims, rat primary cardiomyocytes culture and H9c2 cell line will be used in in 
vitro assays. Cell death will be induced using tert-butyl hydroperoxide (t-BHP) or isoproterenol (ISO), 
and viability will be followed by flow cytometry using propidium iodide. Cell metabolism will be 
assessed through resazurin based assay. Mitochondrial role will be study by assessing mitochondrial 
population through flow cytometry using a specific mitochondrial dye, and by mitochondrial DNA 




















































3. Materials and Methods  
 
3.1. Berries Driven (Poly)phenols 
 
 Recent work done by Disease and Stress Biology Laboratory (Dsb Lab.), within (poly)phenols 
bioavailability, identified and quantified a great array of (poly)phenols metabolites  circulating in 
human plasma after consumption of a (poly)phenol rich juice. Furthermore it was also measured the 













Catechol-O-Sulfate, Pyrogallol-O-Sulfate, and 1-Methylpyrogallol-O-Sulfate were the 
(poly)phenols metabolites used in all experiments, they were used in the concentrations in which they 
were identified in plasma 12, 6, and 3 µM respectively 36. These metabolites were identified in a 
previous work circulating in human plasma for a period of at least 2 h. Experimental conditions were 
chosen based on the human intervention studies, mimicking the concentrations found in plasma and 
resilience time. Synthesis of all (poly)phenols was performed previously within Disease and Stress 
Biology Laboratory as described elsewhere 36. 
3.2. Cell Culture H9c2 differentiation  
 
H9c2 cell line (provided by Dr. Catherin Brenner), was cultured in plating medium [89% (v/v) 
Dulbecco’s modified Eagle’s medium (DMEM) medium supplemented with 4.5 g/L of glucose, 0.11 g/L 
of sodium pyruvate and L- glutamine (Sigma®), 10 % (v/v) Fetal Bovine Serum (FBS, Sigma®), and 1% 
(v/v) 50 U/mL of penicillin and  50 μg/mL of streptomycin (Sigma®)], in a 75 cm2 tissue culture flasks 
(Starstedt), at 37 oC in a humidified atmosphere of 5 % CO2. Cell medium where changed every 2-3 
days, and cells were subculture when reached 70-80 % of confluence in order to prevent differentiation 
into smooth muscle cells. H9c2 cells where detached from the 75 cm2 tissue culture flasks by removing 
the medium, then differentiation was induced by changing the medium serum from 10 % (v/v) FBS to 
1 % (v/v) Horse Serum (HS, Gibco®) followed by the addition of 1 μM of all trans-retinoic acid. Firstly 
H9c2 cells were plated at a density of 3 x104 cell/mL and cultured for 1 day in medium with 10 % (v/v) 
FBS, in order to allow for cell attachment and growth. Secondly media serum was changed to 1% (v/v) 
HS with addition of 1 μM of all trans-retinoic acid, and cells were cultured for 5 more days with a daily 
medium change performed in a low light environment. Finally cell culture was maintained in 







Figure 3-1 – Schematic representation of the different berry driven (poly)phenols used. 
(A) Catechol-O-Sulfate, (B) Pyrogallol-O-Sulfate, (C) 1-Methylpyrogallol-O-Sulfate. 
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3.3. Isolation of neonatal rat cardiomyocytes   
 
Cardiomyocytes were isolated from rat pups (Wistar rats) that were 2-3 days old, all animals 
were rapidly decapitated, hearts were removed and atria excised then the ventricles were minced in 
ADS buffer [0.12 M NaCl (Sigma®) , 0.018 M Hepes (Sigma®), 1.36x10-3 M NaH2PO2 (Applichem), 
5.55x10-3 M glucose (Sigma®), 5.37x10-3 M KCl (Merck), 4.06x10-4 M MgSO4 (Alfa Aesar)]. Ventricular 
tissue in ADS was transferred to a bottle and ADS solution was removed as much as possible. After ADS 
removal, it was added 3 mL of enzymatic solution made with 7 U Collagenase II (Roche) and 30 mg of 
Pancreatin (Sigma®) in 60 mL of ADS. Tissue homogenate was placed in a magnetic stirrer and spun at 
low speed for 20 min, at which point the solution is removed from the undigested tissue and set aside, 
while it is added 3 mL of the same enzymatic solution, this procedure was repeated until all tissue was 
digested. Collected fractions were added to 500 μL of New Born Calf Serum (NBCS, Gibco®) and 
centrifuged for 5 min at 524 g after which the supernatant was discarded and the pellet resuspended 
in 1 mL of NBCS, and stored at 37 oC. After complete digestion, all fractions collected were pooled 
together and centrifuged for 5 min at 524 g, the supernatant was discarded and pellet was 
resuspended in 4 mL of 1x ADS. In order to obtain a purified cardiomyocytes fraction the solution was 
added to a two phase discontinued Percoll (Sigma®) gradient, made from a bottom part with 65% 
Percoll and a top part with 45% Percoll. Percoll discontinued gradient was centrifuged for 30 min at 
2095 g. Purified cardiomyocyte fraction was recollected and cells were plated in plating medium [ 68% 
(v/v) DMEM GlutaMAX supplemented with 1 g/L of glucose, 0.11 g/L of sodium pyruvate (Gibco®), 17% 
(v/v) Medium 199 (Sigma®) supplemented with 2.2 g/L of sodium bicarbonate and 0.1 g/L L-glutamine, 
10% (v/v) HS, 5% (v/v) NBCS, 1% (v/v) L-glutamine (Sigma®)], at a concentration of 7.4x104 cell/mL in 
multiwell plates coated with 0.1 % (w/v) gelatin (Sigma®) 49. 
Throughout all experimental procedure, cells were maintained in plating medium with a 
medium change performed every three days until desirable confluence reached. 
 
3.4. Cell treatment 
 
In order to determine the cytoprotective capacity of the berries driven (poly)phenols (BDP), 
both neonatal rat primary cardiomyocytes and H9c2 cell line after reaching the desired confluence (50 
% of confluence for H9c2 and neonatal cardiomyocytes) were primarily treated for 2 hours with the 
different BDP. After treatment, cells were washed with 1x Phosphate buffered saline (PBS pH 7.2, 
Gibco®) and incubated with the cell death inducers: tert-butyl hydroperoxide (t-BHP, Sigma®) for 24 h 
or with isoproterenol (ISO, Sigma®) for 48 h. tert-Butyl Hydroperoxide was used in order to produce 
extensive oxidative damage, while ISO was used to mimic the catecholamines release that occurs 
during heart failure.  
 
3.5. CellTiter-Blue cell viability assay 
 
CellTiter-Blue cell viability assay was performed on H9c2 cell line to measure cell metabolic 
capacity. H9c2 cell were plated in 96 well plates and after cell treatment described above (for 
cytoprotection evaluation), cells were washed with 1x PBS and incubated with CellTiter-Blue® reagent 
(Promega) for 4 h at 37 oC as manufacture instructions. The fluorescence signal from the reduction of 







3.6. Flow cytometry for evaluation of viability and mitochondrial population 
 
Flow cytometry analysis was performed on neonatal rat primary cardiomyocytes or H9c2 cell 
line that were plated in 24 wells plates.  All samples received the same treatment, supernatant from 
wells was collected into eppendorfs and cells where washed one time with 100 μL of PBS that was 
collect in to the same eppendorf with the supernatant of each well. It was added to every well 100 μL 
of Accutase® (Gibco®) for 30 min in order to detach cells. After incubation, Accutase® activity was 
stopped by adding the previously stored supernatants. The resulting suspension was transferred in to 
eppendorfs and centrifuge at 350 g for 5 min, after which the supernatant was discarded and the pellet 
was resuspended in 300 μL of PBS with the fluorochrome Propidium Iodide (PI, Invitrogen) to evaluate 
cell viability or MitoTracker Deep Red FM (MTDR, Invitrogen) to evaluate mitochondrial population 50.  
The staining for PI was performed on ice and in the dark for 15 min for MTDR the staining was 
performed at room temperature (RT) and in the dark for 30 min. All results were acquired using Becton 
Dickinson FACSCalibur equipped with a low-power air cooled 15 mW blue (488 nm) argon laser, from 
which 3 colours can be detected by the band-passes 530/30 (FL1), 585/42 (FL2), and the long-pass 670 
(FL3). There is also a red (635 nm) diode laser, from which 1 colour can be detect by the band-pass 
661/16 (FL4). From each sample at least 5,000 events were obtained, and all results were analyzed 
using FlowJoX software.  
Analysis was performed using forward light scatter (FSC) vs orthogonal light scatter (SSC) for 
gating. Further analysis was performed using a plot of FSC area vs FSC height to distinguish doublets 
from single cells in order to choose the single cell subset. Within the single cell subset it was possible 
to acquire the percentage of cell viability in the PI experiment by using a FL3 plot to gate the percentage 
of PI negative and positive cells. In the experiment with MTDR it was possible to measure the variations 
in the mitochondrial population within the single cell subset by using a median fluorescence intensity 
vs FL4 plot analysis 50. 
3.7. Immunofluorescence  
 
Immunofluorescence staining was performed in fixed cells in 4% (w/v) of paraformaldehyde 
with 4% (v/v) sucrose for 10 min at room temperature. After fixation cells were washed three times 
with PBS and incubated with blocking buffer containing 0.1% (v/v) Triton (Merck) and 3% (w/v) BSA 
(Sigma®) in PBS for 1 h. For Troponin T, staining cells were incubated with anti-Troponin T, cardiac 
isoform ab-1 (mouse monoclonal, 1:100, Thermo Scientific) overnight at 4 oC. The cells were then 
washed three times with PBS, and were incubated with goat anti-mouse Alexa Fluor 488-conjugated 
antibody (1:500, Abcam) for 2 hours at RT. To visualize the nuclei, cells were counterstaining with a 
drop of ProLong®Gold antifade reagent with 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen) for 10 
min. All fluorescence images were captured using a fluorescence microscope (Leica DMRA2). Analysis 
and treatment of the captured images was performed using Fiji software. 
3.8. Western blot  
 
Cells cultured in 6 wells plates were submitted to protein extraction with Radio-
Immunoprecipitation Assay (RIPA) buffer [50 mM Tris (CarlRoth® – Schoemperlenstr, Karlsruhe, 
Germany); 150 mM NaCl (Sigma®); 0.1% (w/v) Sodium dodecyl sulfate (SDS, Merck); 0.05% (w/v) 
sodium deoxycholate (Sigma®); 1% (v/v) NP-40 (Sigma®); 0.05% (v/v) cocktail protease inhibitors 
(AppliChem) ; and 0.4% (v/v) DNAse (Roche)] were added. Cells were lysed with the previous solution 
on ice for 5 min. following an overnight storage at -80 oC, after which the wells were scraped using a 
cold plastic cell scraper. Cell suspension was gently transfer into eppendorfs and stored at -80 oC until 
used. Protein quantification was then processed using the Bradford quantification kit from Bio-Rad.  
It was used 50 µg of protein per well, and both the protein samples as well as the prestained protein 
marker VI (Applichem)  were subjected to a sodium dodecyl sulphate – polyacrylamide gel 
electrophoresis (SDS-PAGE)  in 10% (w/v) and 1.5 mm thickness  acrylamide gel, at 200 V for 
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approximately 40 min. The electrophoresis buffer was composed by 25 mM Tris-base, 190 mM glycine 
and 0.1% (w/v) SDS. 
Protein electrophoretic transfer occurred after SDS-PAGE gel, and polyvinylidene fluoride 
(PVDF) membrane (Bio-RAD) were assembled in the transfer cell (Trans-Blot® Turbo™ Transfer System, 
BioRad), and transference was carried out at approximately 25 V for 7 min at RT according with 
manufacture instructions. 
After transfer, membrane was rinse in methanol for 1 min. and then  blocked with 5% (w/v) 
membrane blocking agent (MBA, GE Healthcare) in Tris-buffered saline (TBS) containing 0.01% (v/v) 
Tween20® (Sigma®) (TBST), for 1 hour at RT. Membrane was then incubated with primary antibody 
anti-Akt (rabbit monoclonal, 1:1000, Cell Signaling)  or anti-phospho Akt Ser473 (rabbit monoclonal, 
1:1000, Cell Signaling) and left overnight at 4 oC, after which it was washed three times in TBST for       5 
min. each, and incubated  with secondary antibody (goat  anti-rabbit horseradish peroxidase (HRP) – 
conjugated, 1:2500, Thermo Fisher Scientific Inc.) for 2 h at RT. Rabbit anti-actin primary antibody 
(1:500, Santa Cruz Biotechnology) was used as loading control, along with secondary antibody goat 
anti-rabbit HRP – conjugated secondary antibody (1:2500, Thermo Fisher Scientific Inc.). All antibodies 
were diluted in 5% MBA. Antibody detection was performed with a chemiluminescent substrate 
(FemtoMax Super Sensitive Chemiluminescent HRP Substrate, Rockland Inc.) and membrane images 
were acquired in the Molecular Imager Chemidoc XRS (Quantity One© software 4.6.6, BioRad). 
 
3.9. Quantitative-Polymerase chain reaction (Q-PCR) 
 
For quantification of mitochondrial DNA, genomic DNA was extracted from neonatal rat 
primary cardiomyocytes using High Pure DNA isolation kit (Roche Diagnostics), according to the 
manufacturer’s instructions. Assessment of DNA quality and yield, samples were analyzed with a 
NanoDrop 2000c spectrophotometer (Thermo Scientific) and DNA integrity and contamination were 
determined by DNA visualization in a 1% agarose gel, stained with ethidium bromide. PCR was 
performed using specific forward and reverse primers designed for the mitochondrial cytochrome b 
(mtCyt b) gene (forward: 5′-TTCATGTCGGACGAGGCTT-3′, reverser: 5′-TCCTCATGGAAGGACGTAGC-3′) 
and for the nuclear glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene                                                   
(5′-CCTTCATTGACCTCAACTACAT-3′, 5′-CCAAAGTTGTCATGGATGACC-3′), respectively. Fast Start DNA 
Master Plus SYBR Green I (Roche Diagnostics) was used, according to the manufacturer’s instructions, 
with the experimental run protocol: denaturation program was 95 °C for 10 minutes, followed by 45 
cycles of 95 °C for 10 seconds, 60°C for 10 seconds and 72 °C for 10 seconds. 
 
3.10. Cell beating rate measurement  
 
 Cell beating rate was acquired by placing control and treated cells under the 10x/0.25NA 
dry objective lens on a Nikon Eclipse Ti-U inverted bright field light microscope. Images were recorded 
with a high speed FASTCAM MC2 camera (Photron Europe, Limited) and controlled with PFV (Photron 
FASTCAM Viewer) software. All measurements were acquired by Pedro Sampaio, from the Cilia 
Regulation and Disease laboratory from CEDOC. For each condition it was measured 20 different cells 
per condition by acquiring a total of 1500 frames at a rate of 60 frames per second. In order to quantify 
changes in cell beating background surface shape was removed, and images were converted to 
grayscale with 16 bits per sample pixel. This method permit to measure the difference in light intensity 
throughout time, as beating cardiomyocytes will diffract light differently during contraction. Analysis 
and treatment of captured images was performed using Fiji software, which calculates cell beating 









3.11. Statistical analysis 
 
Reported results were statistically evaluated using SigmaPlot 11 software (Systat Software 
Inc.). Box-and-Whiskers plots were analyzed by Kruskal-Wallis one way analysis of Variance on ranks 
and compared by Dunnetts Method with a confidence level of 95%. Remaining data were analyzed by 
one way analysis of variance (one way ANOVA) and compared by Tukey honest significant difference 



























































4. Results  
 
(Poly)phenols intake as long been associated with a reduced risk of CVD development, 
however their mechanisms of action continues to elude the scientific community. This study aims to 
evaluate the effects in cardiac cells induced by BDP metabolites capable of reaching the human 
circulatory system. A previous human intervention study for identification of circulating  BDP 
metabolites was the base for choosing the metabolites tested herein36. The metabolites used were 
Catechol-O-Sulfate, Pyrogallol-O-Sulfate, and 1-Methylpyrogallol-O-Sulfate, as their concentration was 
the highest found in human plasma 36. 
 
4.1. H9c2 cells differentiation into cardiomyocytes 
 
With the purpose of studying in vitro the cytoprotective effect and the associated mechanisms 
involved with the (poly)phenols, it was chosen the  H9c2 cell line. This cell line is isolated from the 
ventricular part of a thirteenth-day rat heart embryo and presents a myoblastic proliferative 
phenotype while maintained in 10 % (v/v) FBS containing culture media 48. H9c2 cells have been applied 
in several in vitro studies, as a model for cardiac diseases, namely hypertrophy, cardiotoxicology, 
ischemia/ reperfusion injury and oxidative stress as well as in studies of mechanisms for cardiac 
differentiation 32,48,51–54. Most studies are performed with undifferentiated H9c2 cell line which can rise 
questioning into the applicability of the results, as it is described to have a less physiological response 
54. H9c2 cell line has the capacity to differentiate into either skeletal or cardiac muscle-like cells 
depending on whether or not the serum reduction to 1 % is accompanied by a daily treatment with 1 




Troponin T is a thin filament protein involved in the regulation of muscle contraction. Although 
cardiac troponin T isoform is expressed transiently in immature skeletal and cardiac muscle, in adult 
cells is expressed exclusively by cardiac muscle cells 55. Therefore troponin T expression may be used 
as a marker for cardiac cells 56.  
Following cardiomyocyte differentiation protocol into cardiac muscle-like cells, it was possible 
to verify an increase in cardiac troponin T isoform expression throughout the first two days (Fig.4-1).  
At the third day, cells appear to have lost the ability to undergo mitosis, organized structures 
containing cardiac troponin T isoform start to be formed, and cells acquire a different morphology. 
After five days of differentiation H9c2 cells had acquired a cardiac-like cell shape. During differentiation 
process it was possible to confirm that H9c2 cells express specific cardiac markers, making it a more 
representative model.  
 In conclusion the differentiation protocol was successful, allowing for this in vitro cell model 
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Figure 4-1 – Morphology change of H9c2 cells after induced differentiation into cardiac muscle-like cells,  
showed by immunofluorescence staining. Cardiac troponin T isoform stained in green fluorescence, nucleus 
stained with DAPI in red. H9c2 cells with differentiation treatment: (A) 0 days, (B) 1 day, (C) 2 days, (D) 3 days, 
(E) 4 days, (F) 5 days. 
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4.2. Differentiated H9c2 cell line viability with t-BHP 
 
As oxidative stress is the mainly cause of CVDs, oxidative stress induced cell death was chosen 
as a model to study the potential cytoprotective effects of BDP. As it is a well-known membrane 
permeant pro-oxidant agent and inhibitor of mitochondrial function, t-BHP was used as oxidative 
agent. Exposition of H9c2 cells to t-BHP promotes nucleotide degradation and adenosine formation, 
increases ROS production, alterations in mitochondrial network, chromatin condensation and nuclear 
shrinkage 51,57. 
Cytoprotective ability of BDP metabolites was tested against an oxidative stress model with t-
BHP 51. Differentiated H9c2 cells were treated with 80 and 120 μM t-BHP for 24 h, not to give an acute 
damage but instead a mild and chronic stress.  
Concentrations of t-BHP were chosen through measurement of the half maximal effective 
concentration (EC50), from metabolic capacity. After treatment for 24h with 80 μM of t-BHP reduced 
in 50 % metabolic capacity, while treatment with 120 μM of t-BHP reduced cell metabolic capacity in 
80 % (results not shown). 
Although 80 µM of t-BHP for 24 h was the EC50 for metabolic capacity, it was not enough to 
diminish in 50 % viability of differentiated H9c2 cells, monitored by flow cytometry. However this 
concentration was enough to cause significant cell death.  
 
 
Differentiated H9c2 cells treated with 80 µM of t-BHP presented a 10 % diminish in viability 
comparatively to control. This viability reduction was significantly prevented when cells were pre-
treated with BDP metabolites, suggesting a cytoprotection (Fig.4-2). However treatment with 120 μM 
t-BHP induced an excessive death, making it impossible to obtain conclusive results from the BDP 
metabolites effect other than the incapacity to protect against this high stimulus. Nevertheless, 
evaluation through flow cytometry using PI only allows to distinguish viable cells from late apoptotic 





































Figure 4-2 – Differentiated H9c2 cells viability after being pre-treated for 2 h with the different BDP metabolites and treated 
for 24 h with two concentrations of t-BHP.BDP concentrations used where: Catechol-O-Sulfate 12 μM, 1-Methylpyrogallol-O-
Sulfate 3 μM, and Pyrogallol-O-Sulfate 6 μM. Cell viability was determined through cell permeability to PI by flow cytometry. 
Data are mean ± SD from three independent experiences. *** P < 0.001, ** P < 0.05 versus Control; # # P < 0.05 versus Control 













4.3. Differentiated H9c2 cell line viability with ISO 
 
Although incubation with t-BHP is a frequently utilized oxidative stress model, it is not a cardiac 
specific toxicant as ISO, which is a β-adrenergic agonist. β-adrenergic receptors (β-AR) are essential for 
cardiac functions as regulators of cardiac performance. Adrenergic amines released by the sympathetic 
nervous bind to β-AR, resulting in an increase in cardiac contractility, frequency, and rate of relaxation 
58. During a heart failure episode there is an increased release of catecholamines in an attempt to 
restore homeostasis. Nevertheless an extensive and excessive signaling of catecholamine on β-AR 
leads to loss of adrenergic pathways, decreased contractility, changes in gene expression, calcium 
overload, and ultimately cell death 7,53. 
Concentration and time period for ISO treatment were chosen through measurement of EC50 
from metabolic capacity. After treatment for 48 h with 200 µM ISO, metabolic capacity was reduced 
by 50 % (data not shown).  
 
Treatment with 200 µM ISO for 48 h reduced cell viability in 50 %. These results were obtained 
through cell permeability to PI by flow cytometry, and showed a similar EC50 to the one obtained when 
measuring metabolic capacity.  
Differently from the results obtained with t-BHP (Fig.4-2), pre-treatment with BDP metabolites 
did not possess cytoprotective effects against ISO treatment. Additionally, Pyrogallol-O-Sulfate 
appears to significantly increase ISO toxicity, while the remaining BDP do not affect cell viability (Fig.4-
3). Catechol-O-Sulfate and 1-Methylpyrogallol-O-Sulfate seem to protect against oxidative injury, but 
do not protect against ISO induced damage suggesting that BDP targets may not be directly connected 































Figure 4-3 – Differentiated H9c2 cells viability after being pre-treated for 2 h with the different BDP metabolites and 
treated for 48 h with ISO. BDP concentrations used where: Catechol-O-Sulfate 12 μM, 1-Methylpyrogallol-O-Sulfate 3 
μM, and Pyrogallol-O-Sulfate 6 μM. Cell viability was determined through cell permeability to PI by flow cytometry. 
Data are mean ± SD from three independent experiences, ** P < 0.05 versus Control; # # P < 0.05 versus Control with 














4.4. Cell metabolic capacity 
 
In order to evaluate (poly)phenols effect in overall metabolic capacity, differentiated H9c2 cells 
were pre-treated with BDP metabolites for 2h. Cell metabolic capacity was assessed through CellTiter-
Blue viability assay, in which reduction of resazurin to resorufin by mitochondrial, cytosolic, and 
microsomal enzymes was measured 59,60. 
 
Berries driven (poly)phenols metabolites appear to influence cell metabolic capacity, as shown 
in Fig.4-4. Through the obtained data it appears 1-Methylpyrogallol-O-Sulfate increases metabolic 
capacity, while the remaining tested metabolites diminish it. However, PI permeability results have 
shown that all BDP metabolites in the concentrations tested were not cytotoxic. These results suggest 
that, BDP metabolites possess two different mechanisms of action. Catechol-O-Sulfate and Pyrogallol-
O-Sulfate are capable to reduce metabolic capacity as reflected by the reduction in enzymatic activity 
responsible for resazurin reduction to resorufin. Moreover, 1-Methylpyrogallol-O-Sulfate promotes an 
increase of resazurin reduction. Nevertheless, given these results it would be interesting to further 
investigate cell metabolic changes, in order to comprehend the fully extend of BDP metabolites 
influence over cell metabolism. 
 
4.5. Neonatal rat cardiomyocytes viability with t-BHP 
 
Primary cultures of neonatal rat cardiomyocytes are as H9c2 cultures, a well-established model 
for studying CVDs, but contrary to H9c2, these cells possess intrinsic cardiac beating activity, and allow 
for a metabolic response closer to one observable in vivo 61.  
Treatment of cells with 80 μM t-BHP showed excessive death, making it impossible to conclude 
if there was any real influence from pre-treatment with (poly)phenols metabolites (Fig.4-5). One 
unanticipated result was the slight cytotoxicity presented by Catechol-O-Sulfate. This one-off 

































Figure 4-4 – Differentiated H9c2 cells metabolic capacity measured after being pre-treated for 2 h with the different 
BDP metabolites. BDP concentrations used where: Catechol-O-Sulfate 12 μM, 1-Methylpyrogallol-O-Sulfate 3 μM, and 















Neonatal rat cardiomyocyte cells were substantially more susceptible to treatment with 80 µM 
t-BHP than differentiated H9c2 cells. These results imply that even though differentiating H9c2 cells to 
cardiac muscle like cells helps obtaining a more physiologic response, H9c2 cells are still an 
immortalized cell line making them much more resilient to oxidative stress than a primary cell culture. 
These differences could explain the discrepancy in the obtained viability results from the different cell 
models.  
Using 80 µM t-BHP for 24 h did not make it possible to study the BDP effects in neonatal rat 
cardiomyocytes, given the excessive cell death. Other concentrations of t-BHP were tested, such as 20 
and 40 µM for 24 h of incubation (Fig.8-1 in appendix), which revealed 40 µM t-BHP to be the 
concentration closer to EC50. Further experiments will be performed using 40 µM t-BHP and BDP to 
confirm the protective ability previously detected when using differentiated H9c2 cells (Fig.4-2) 
Although not having observed cytoprotection with neonatal rat cardiomyocytes, comparing 
both models, this model is closer to in vivo than the H9c2 model, and thus it was decided to use only 
neonatal model for the remaining experiments. 
 
4.6. Neonatal rat cardiomyocytes viability with ISO 
 
As neonatal rat cardiomyocytes are a closer to in vivo model than H9c2 cells, it was decided to 
also test ISO, in order to measure a more in vivo like response. This treatment produce a similar 
response in cells to the one applied to the differentiated H9c2 cells. It was applied 200 µM ISO for 48 
h, which is described to lead to impairment of cardiac cell functions, such as a reduced contractility 




Figure 4-5 – Neonatal rat cardiomyocytes viability after being pre-treated for 2 h with the different BDP metabolites and 
treated for 24 h with 80 μM t-BHP. BDP concentrations used where: Catechol-O-Sulfate 12 μM, 1-Methylpyrogallol-O-
Sulfate 3 μM, and Pyrogallol-O-Sulfate 6 μM. Cell viability was determined through cell permeability to PI by flow cytometry. 
Data are mean ± SD from three independent experiences. *** P < 0.001, ** P < 0.05 versus Control; # # # P < 0.001 versus 
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When exposed to 200 μM ISO, primary cultures of neonatal rat cardiomyocytes showed an 
attenuated decrease in viability comparatively to the results obtained with t-BHP treatment. Even so 
BDP metabolites were not efficient in preventing a diminishing in viability against 200 µM of ISO (Fig. 
4-6). Additionally, with the exception of Pyrogallol-O-Sulfate that significantly increased ISO induced 
death, the remaining BDP metabolites do not increasing ISO toxicity. These results go into accordance 
with the ones previously obtained by differentiated H9c2 cells and ISO treatment (Fig.4-3), further 
supporting that BDP metabolites cannot prevent ISO induced cell death in the conditions tested. 
 
4.7. Cell beating activity 
 
Despite none of the BDP metabolites showed cytoprotective effects in neonatal rat 
cardiomyocytes, it is still hypothesised a beneficial influence in physiological heart hypertrophy. An 
animal study conducted by Dr. Catherine Brenner (Paris-Sud University, France), in collaboration with 
our group, was performed using Dahl-salt sensitive rats (confidential data not published), where the 
berries mixture used was equal to the one used in the human intervention study 36.  
Dahl-salt sensitive rats are a well-accepted animal model for hypertensive and diastolic heart 
failure studies, as they can also be preconditioned by diet. They exhibit many phenotypic traits 
common with hypertensive disease observed in humans, such as high blood pressure, salt sensitivity, 
insulin resistance and hyperlipidaemia. 
The results obtained from the animal study performed by our collaborators showed that 
hypertension-induced by a high salt diet (HS diet) was associated with cardiac hypertrophy and a 
decrease in cardiac functions. Interestingly, HS diet supplemented with the berries mixture (HSB diet) 
decrease in mortality comparatively to rats fed only with HS diet. Moreover, HSB diet prevented 
cardiac damage independently of changes in systolic pressure, also increase in heart weight index was 
attenuated in rats fed with HSB diet comparatively to the ones fed with HS diet (confidential results). 
Direct extrapolation from induced responses in rat to human are not possible, as both species 
possess different metabolic rates and it has been proven that findings in rat tissue do not always 
reproduce the metabolism observed in human.63 However it is plausible to assume that even though 
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Figure 4-6 – Neonatal rat cardiomyocytes viability after being pre-treated for 2 h with the different BDP metabolites 
and treated for 48 h with ISO. BDP concentrations used where: Catechol-O-Sulfate 12 μM, 1-Methylpyrogallol-O-
Sulfate 3 μM, and Pyrogallol-O-Sulfate 6 μM. Cell viability was determined through cell permeability to PI by flow 
cytometry. Data are mean ± SD from three independent experiences, *** P < 0.001 versus Control; # # # P < 0.001 versus 
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be present in the Dahl-salt sensitive rat plasma. Presently, the berries metabolites bioavailability is 
being evaluated in plasma, urine, heart, liver and kidneys collected from the animal study performed 
by Dr. Catherine Brenner. When new metabolites are detected, they will be chemically synthesized 
and include in future in vivo assays. 
Taking into consideration Dr. Catherine Brenner results and the fact that pathologic heart 
growth from hypertension leads to reduced cardiac contractility, exploiting this BDP effects on cell 
beating activity could shed some light on the extent of their effects.  
Prolonged exposure to ISO leads to cell beating impairment, making it possible to use this 
model to evaluate BDP effects in beating rate of ISO treated neonatal rat cardiomyocytes after 24 and 
48 h (Fig. 4-7, 4-8). As cell death becomes evident after 48 h of ISO treatment, time points were chosen 
in order to determine if contractile dysfunction occurred prior or simultaneously to induced cell death.  
Through the box-whiskers plot it is possible to directly evaluate overall cell synchronization by 

























0 µM ISO 200 µM ISO 
Figure 4-7 – Neonatal rat cardiomyocytes cell beating measurement, after a 2h pre-treatment with the different BDP 
metabolites and treated for 24 h with ISO. BDP concentrations used where: Catechol-O-Sulfate 12 μM, 1-Methylpyrogallol-O-




























It was verified that treatment with 200 μM ISO for 24 h does not induce significant decrease 
in cardiac contractile function (Fig.4-7), contrary to the 48 h time point where significant damage to 
cardiac contractile function can be observed (Fig.4-8). 
1-Methylpyrogallol-O-Sulfate and Pyrogallol-O-Sulfate appear to after 48 h of ISO treatment, 
prevent loss of contractile functionality and increase beating synchronization relatively to the 
remaining conditions.  
Pre-treatment with BDP metabolites maintained a normal beating rate comparatively to 
control without ISO treatment (Fig.4-7), which indicates that they do not possess chronotropic effects. 
Nevertheless cells that were pre-treated with BDP metabolites and treated with ISO showed a better 
synchronization and elevated beating rate compared to control treated with ISO (Fig.4-8).  
These results are very promising, as they suggest an interaction between BDP metabolites and 
pathways responsible for contractile regulation. It appears that BDP metabolites per se do not 
influence cardiac beating, only when cells are exposed to ISO. After 24 h of ISO treatment, cells pre-
treated with BDP metabolites do not show difference in beating rate. Nevertheless they are the most 
synchronized ones, as reflected by the lower dispersion between measurements (Fig.4-7). However 
after 48 h of ISO treatment this effect is no longer evident, their synchronization becomes very similar 
to the controls, while maintaining a normal beating rate. 
There is still need for future experiments to also measure cell length and evaluate the 
expression of specific cardiac hypertrophy protein markers, in order to associate this changes with a 
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Figure 4-8 – Neonatal rat cardiomyocytes cell beating measurement, after a 2h pre-treatment with the different BDP 
metabolites and treated for 48 h with ISO. BDP concentrations used where: Catechol-O-Sulfate 12 μM, 1-
Methylpyrogallol-O-Sulfate 3 μM, and Pyrogallol-O-Sulfate 6 μM. Outliers are identified as ●. ** P < 0.05 versus 
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4.8. Protein phosphorylation induced by BDP 
 
Recently Akt has been gaining attention from the scientific community, as it has been 
demonstrated its importance in cardiac development, suppressing fetal genes expression, and release 
of cytochrome c and AIF from mitochondria 13,64. 
In order to study a possible interactions between BDP metabolites and Akt activation, efforts 
were made to measure Akt phosphorylation levels by western blot. Despite numerous attempts, 
probably due to technical problems (data not shown), it was not possible to visualize phosphorylated 
Akt. Measuring Akt phosphorylated turned into a real challenge in which the reason for failure is still 
unknown. 
 
4.9. Mitochondrial population 
 
Mitochondria are very important organelles, as they are the cells main source of energy and 
also control apoptosis14,15. During pathological events there is an increase in energy demand, which 
leads to a necessity in increasing total mitochondrial population, in order to keep up with the energy 
demand 13.  
Therefore, to test BDP metabolites influence in mitochondrial population, it was evaluated 
total mitochondrial population regardless of the mitochondrial membrane potential, in neonatal rat 
cardiomyocytes  through the MTDR staining method 50. 
Recent studies have shown that excessive oxidative stress can induce an increase in 
mitochondrial population by damaging the autophagic capacity of the cells57. In order to prevent false 
positives all data referent to mitochondrial population was acquired without any toxicant treatment. 
 
 
After cell pre-treatment with the BDP metabolites, it was possible to observe that all 
compounds are able to significantly increase mitochondrial population under physiologic conditions 
(Fig. 4-9). These results demonstrate that BDP (poly)phenols increase mitochondrial population, which 
can implicate an improvement on  mitochondrial metabolism. Further studies where perform to 










































Figure 4-9 – Effects of BDP metabolites on the mitochondrial population of  neonatal rat cardiomyocytes cells pre-treated 
with different BDP metabolites for 2h and cells harvest after 24 h. BDP concentrations used where: Catechol-O-Sulfate 
12 μM, 1-Methylpyrogallol-O-Sulfate 3 μM, and Pyrogallol-O-Sulfate 6 μM. Data are mean ± SD from three independent 
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4.10. Mitochondrial DNA 
 
In order to increase reliability from the MTDR method measurements, it was evaluated the 
mtDNA through Q-PCR using GAPDH gene as an endogenous reference gene and mtCyt b as target 
gene.                     
 
It was observe that of all BDP metabolites tested, only pre-treatment with 1-Methylpyrogallol-
O-Sulfate seems to increase mtDNA content relatively to control (Fig. 4-10). It was only possible to 
perform one biological replicate so it is not possible to assume definitive conclusions from these 
results. Even so it can be observed a clear tendency in the increase of mtDNA, resulting from the BDP 
metabolites pre-treatment.  
It has been shown that in presence of autophagic dysfunction, there is mitochondrial 
accumulation but a decrease in total mtDNA 18,57. However, the data obtain supports the hypothesis 
that BDP metabolites induce increase in mitochondrial population probably due to mitochondrial 
biogenesis. Further experimental data are necessary to clarify whether or not this increase is due to 
mitophagy dysfunction 
Nonetheless further assays are necessary, such as autophagosome colocalization techniques 
or western blot analysis of specific transcription factors associated with mitochondrial biogenesis. Only 











































Figure 4-10 – Effects of BDP metabolites on the mtCyt b gene quantity. Neonatal rat cardiomyocytes were pre-treated with 
different BDP metabolites for 2h and cells harvest after 24 h. BDP concentrations used where: Catechol-O-Sulfate 12 μM, 




































































The aim of this study was to evaluated cytoprotection and associated mechanisms in 
cardiomyocytes by different (poly)phenols metabolites, against two distinct cell death inducers, t-BHP 
and ISO. Both inducers were used in concentrations and time points to mimic progressive 
cardiovascular diseases, like congestive heart failure or hypertensive heart disease that can be 
attenuated or even prevented through diet.  
 For the first time, it was possible to demonstrate compelling evidence of possible health 
benefits against CVDs, derived from BDP metabolites pre-treatment. Berries driven (poly)phenols 
metabolites have shown to be able to protect cells against an unspecific insult produced by t-BHP 
(Fig.4-2). However, with a prolonged insult of ISO, cells were not protected. Of the BDP metabolites 
tested, Pyrogallol-O-Sulfate aggravated induced cell death, while the remaining BDP metabolites did 
not present the same response (Fig.4-3; 4-6). This further demonstrates how complex the functional 
interactions between BDP metabolites and cardiac cells pathways are during a chronicle insult.  
It was also observed a clear influence of BDP metabolites over mitochondria, the most 
important organelle in cell metabolism. Pre-treatment with BDP metabolites induced a significant 
increase in mitochondrial population (Fig. 4-9), that can be supported by the tendency in mtDNA raise, 
observable from Q-PCR data (Fig.4-10). Confirmation of these results will be very relevant, as during 
CVDs there is an incremental need for ATP, and mitochondria are the principal ATP generator. These 
results suggest a possible increase in ATP production, associated with the mitochondrial population 
increase, which could bridge the energy gap felt by cells during CVDs. 
Although it was observed an increase in mitochondrial population through two different 
methods, it could be argued that mitochondria are accumulating instead of mitogenesis, and even if 
there is an increase in mitochondria population there is no indication that majority is correctly 
functioning. Previews work have shown the ability of different (poly)phenols to either increase 
mitochondrial biogenesis or impair autophagy 65–67. In order to debunk these possibilities it would be 
necessary to perform a quantitative reverse transcription polymerase chain reaction (qRT-PCR) to 
measure the expression level of a mitochondrial biogenesis related gene, such as PGC-1α gene. 
Furthermore it would also be necessary to evaluate mitochondrial membrane potential of the 
mitochondrial population, in order to prove their functionality. 
 An important finding in this work was the ability of BDP metabolites to maintain normal cardiac 
contractile functions without affecting ISO induced cell death (Fig.4-8) which to my knowledge was 
never observed before. These results were most intriguing, as pre-treatment with BDP metabolites per 
se did not influence neither cell beating rate nor cell synchronization. However, when cells were pre-
treated with BDP metabolites and treated with ISO, it is observable a clear improvement in cell 
synchronization at 24 h (Fig.4-7). It was also shown that after extensive damage caused by ISO 
exposition (48 h), cells pre-treated with BDP metabolites presented a cell beating rate similar to the 
control even though there was a diminish in 40 % of viability. 
 Continued stimulation by ISO, induces an increased production of cyclic adenosine 
monophosphate (cAMP) which in turn activates protein kinase A (PKA) 68,69.  Overactivation of cAMP-
PKA that will phosphorylate  an extensive number of proteins, including L-type calcium channels, 
proteins from the contractile apparatus such as troponin I , β-AR, and other G protein-coupled 
receptors, causing a desensitization of the β-AR to further stimulation 69. Regardless of all the 
activation caused by cAMP-PKA, recent studies have shown that apoptosis driven from β-AR 
overactivation, originates from the activation of Ca2+/calmodulin-dependent protein kinase II (CaMKII), 
as changes in L-type calcium channels phosphorylation state will lead to an intercellular calcium 
accumulation. This impairment in calcium handling will result in a dysfunction in the contractile 
mechanism leading to arrhythmias, and finally an excessive accumulation of calcium within 
mitochondrial matrix will lead to apoptosis 69. 
 Taking into consideration the ISO overactivated pathway and the results obtained from cell 
viability and cell beating activity,  it becomes evident the complexity of the functional interaction 
30 
 
between the BDP metabolites and cardiac cells under a pathological stress such as the one induced by 
ISO over exposition.  
Summarizing the results obtain through this thesis, it was hypothesized that BDP metabolites 
may not affect the cAMP-PKA signaling pathway, which is the principal cause for apoptosis from β-AR 
stimulation, but may in fact interact with proteins related to cell contractile functions. Further studies 
are still needed to better understand the complex interactions observed between the BDP metabolites 




























6. Conclusion and Future work 
 
Working with human bioavailable (poly)phenols metabolites in physiological concentrations is 
a step further into  unraveling the true beneficial effects from dietary (poly)phenols ingestion. The 
underlying mechanism behind BDP metabolites effects still alludes us. However data from cell beating 
capacity and mitochondrial population corroborates the possibility of an interaction between BDP 
metabolites and with proteins related to cardiomyocyte contractile functions. 
 Despite these promising results, this research has thrown up many questions in need of further 
investigation. It would be important to optimize the western blot procedure for measuring Akt 
phosphorylation. Considering that cardiac contractility, metabolism, mitochondrial population and 
physiological cardiac hypertrophy are influenced by Akt signaling pathway, it would be possible for Akt 
to be a target for the BDP metabolites 64. Taking into consideration contractibility improvement and 
mitochondrial population increase, it would be plausible to assume such interaction.  
 Assuming that BDP metabolites can increase Akt phosphorylation levels, it would be necessary 
to treat cells with Akt pathway inhibitor (LY294002) and repeat all experiments to prove the possible 
link between Akt pathway and the obtained data. Despite the results obtained from cells beating rate, 
it is necessary to complement this data with, patch clamp experiments to measure variations in calcium 
intercellular concentration and analysis of proteins from the contractile apparatus such as troponin I. 
Measuring these factors will bring us to a closer understanding of the fully metabolic modulation 
abilities possessed by BDP metabolites. 
All insults tested so far were to mimic chronic diseases, such has congestive heart failure. To 
develop a full picture of the preventive potentialities of BDP metabolites, additional studies will be 
needed to cover other types of CVDs, such as myocardial ischemia, hypertension, and cardiomyopathy. 
Pre-treatment with BDP metabolites could possibly diminish the damage caused during a one-off 
cardiovascular incident.  
There is in vivo data showing a positive influence of BDP metabolites in hypertensive rats  by 
limiting animal death and decreasing heart hypertrophy (confidential data). Future work using 
hypertrophic cell models with angiotensin-II 70, will permit to study  the influence of BDP metabolites 
in preventing hypertensive heart disease.  
 A further study with more focus on using BDP metabolites as possible therapeutic agents, 
would be worthwhile. It would be interesting to assess the of BDP metabolites against different animal 
models of CVDs, such as ischemic heart disease, cardiomyopathy, hypertensive heart disease, and 
congestive heart failure . These animal studies would permit to evaluate against which disease, BDP 
metabolites possess a better preventive effect. Subsequently to identifying which disease has a better 
chance to be prevented through BDP metabolites pre-treatment, human trails would be the next step 
in order to fully validate one if not all BDP metabolites tested as novel prophylactic drugs against CVDs. 
Given the growing number of cardiovascular incidents, being able to possibly develop a 
prophylactic drug against CVDs, would be a great achievement. Creating a prophylactic drug from BDP 
metabolites, would help people with a propensity to CVDs keeping a higher quality of life and reduce 
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Figure 8-1  – Neonatal rat cardiomyocytes cell viability determined through cell permeability to PI by flow cytometry, 
after treatment with 20 and 40 µM t-BHP . Data are mean ± SD from one biological replicate. *** P < 0.001, versus 
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